MARKET

INCY

INCY

Incyte Corp
NASDAQ
52.82
+0.10
+0.19%
After Hours: 52.82 0 0.00% 16:03 04/18 EDT
OPEN
52.96
PREV CLOSE
52.72
HIGH
53.15
LOW
52.26
VOLUME
1.83M
TURNOVER
0
52 WEEK HIGH
75.74
52 WEEK LOW
50.27
MARKET CAP
11.86B
P/E (TTM)
19.97
1D
5D
1M
3M
1Y
5Y
CHINA MEDICAL SYSTEM - APPROVAL FROM PHARMACEUTICAL ADMINISTRATION BUREAU OF MACAU
Reuters · 2d ago
Certain Biotech Investors Get an Early Look at Results. Is That Fair? -- Heard on the Street
Biotech companies are increasingly turning to PIPEs, or private investments in public equities. In the first quarter, U.S. Biotechs raised a record $5.7 billion using the approach. Some investors say the PIPE boom is leaving out generalist investors. Some say the deals are a form of legal insider trading.
The Wall Street Journal · 4d ago
Weekly Report: what happened at INCY last week (0408-0412)?
Weekly Report · 4d ago
Press Release: Incyte to Report First Quarter Financial Results
Incyte to Report First Quarter Financial Results on Tuesday, April 30, 2024. Incyte's first quarter financial results conference call and webcast will be held at 8:00 a.m. ET. A replay of the conference call will be available for thirty days.
Dow Jones · 04/11 12:04
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), BioMarin Pharmaceutical (BMRN) and ACADIA Pharmaceuticals (ACAD)
TipRanks · 04/09 02:40
Analysts Anticipate FXH Will Reach $123
NASDAQ · 04/08 10:38
Weekly Report: what happened at INCY last week (0401-0405)?
Weekly Report · 04/08 09:19
INCYTE CORP <INCY.O>: JP MORGAN RAISES TARGET PRICE TO $60 FROM $58
Reuters · 04/08 06:49
More
About INCY
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts clinical development and commercial operations from its European headquarters in Morges, Switzerland and its other offices across Europe, as well as its Japanese office in Tokyo and its Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs.

Webull offers Incyte Corp stock information, including NASDAQ: INCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INCY stock methods without spending real money on the virtual paper trading platform.